Patents Assigned to Medarex, Inc.
-
Patent number: 10072090Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.Type: GrantFiled: January 14, 2016Date of Patent: September 11, 2018Assignees: AMGEN INC., MEDAREX INC.Inventors: Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
-
Publication number: 20140271684Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: ApplicationFiled: November 12, 2013Publication date: September 18, 2014Applicants: Medarex, Inc., ADURO GVAX INC.Inventors: Betty LI, Karin JOOSS, Alan J. KORMAN
-
Publication number: 20140039164Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.Type: ApplicationFiled: August 7, 2013Publication date: February 6, 2014Applicants: Medarex, Inc., Amgen Inc.Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
-
Publication number: 20140004127Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.Type: ApplicationFiled: August 13, 2013Publication date: January 2, 2014Applicants: MEDAREX, INC., AMGEN INC.Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
-
Patent number: 8580247Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: GrantFiled: September 14, 2012Date of Patent: November 12, 2013Assignees: Aduro GVAX Inc., Medarex, Inc.Inventors: Betty Li, Karin Jooss, Alan J. Korman
-
Patent number: 8563694Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.Type: GrantFiled: July 26, 2010Date of Patent: October 22, 2013Assignees: Medarex, Inc., N.V.OrganonInventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
-
Publication number: 20130252327Abstract: Disclosed are methods relating to amplification and expression of a nucleic acid sequence encoding a polypeptide of interest in recombinant cells, and cell lines and polypeptides produced from such methods. The methods disclosed herein permit the amplification of cell lines that express a polypeptide of interest in a relatively short period of time through the use of a bioreactor.Type: ApplicationFiled: January 14, 2013Publication date: September 26, 2013Applicant: Medarex, Inc.Inventors: Alahari Arunakumari, Xiao-Ping Dai, Haile Ghebramariam
-
Publication number: 20130254912Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: June 4, 2013Publication date: September 26, 2013Applicant: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 8529893Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.Type: GrantFiled: May 21, 2012Date of Patent: September 10, 2013Assignees: Amgen Inc., Medarex, Inc.Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
-
Publication number: 20130230530Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Publication number: 20130230534Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: ApplicationFiled: May 9, 2013Publication date: September 5, 2013Applicant: MEDAREX, INC.Inventors: JOSEPHINE M. CARDARELLI, ALISON WITTE, MOHAN SRINIVASAN
-
Patent number: 8518407Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.Type: GrantFiled: April 18, 2012Date of Patent: August 27, 2013Assignees: Amgen Inc., Medarex, Inc.Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
-
Publication number: 20130204033Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: ApplicationFiled: January 29, 2013Publication date: August 8, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Publication number: 20130197259Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: ApplicationFiled: January 29, 2013Publication date: August 1, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Patent number: 8496931Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed.Type: GrantFiled: August 10, 2007Date of Patent: July 30, 2013Assignees: Medarex, Inc., Ono Pharmaceutical Co., Ltd.Inventors: Sarah L. Pogue, Alan J. Korman, Josephine M. Cardarelli, Mohan Srinivasan, Bingliang Chen, Alasdair F. Bell
-
Publication number: 20130189256Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: ApplicationFiled: January 29, 2013Publication date: July 25, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Publication number: 20130171168Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: March 11, 2013Publication date: July 4, 2013Applicants: MEDAREX, INC., AMGEN INC.Inventors: Amgen Inc., Medarex, Inc.
-
Patent number: 8475797Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: August 16, 2011Date of Patent: July 2, 2013Assignee: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josphine M Cardelli, David King, David Passmore
-
Publication number: 20130164292Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: December 28, 2012Publication date: June 27, 2013Applicants: MEDAREX, INC., AMGEN, INC.Inventors: Amgen, Inc., Medarex, Inc.